Sirna Therapeutics to Webcast Presentation at the UBS Global Specialty Pharmaceuticals Conference
April 20 2006 - 8:02AM
PR Newswire (US)
SAN FRANCISCO, April 20 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi
therapeutics company, announced today that Howard W. Robin, Sirna's
President and Chief Executive Officer is scheduled to give a
company presentation at the UBS Global Specialty Pharmaceuticals
Conference on Tuesday, April 25, 2006 at 11:30 a.m. EDT at the
Grand Hyatt in New York City. A live webcast of the presentation
will be available on the Company's corporate web site at
http://www.sirna.com/. Participants are urged to log on to the web
site 15 minutes prior to the scheduled start time to download and
install any necessary audio software. A replay of the webcast will
be available approximately three hours after the live event and
will remain accessible for four weeks, through May 25, 2006. About
Sirna Therapeutics Sirna Therapeutics is a clinical-stage
biotechnology company developing RNAi-based therapies for serious
diseases and conditions, including age-related macular degeneration
(AMD), hepatitis B and C, dermatology, asthma, Huntington's
disease, diabetes and oncology. Sirna Therapeutics completed its
Phase 1 clinical trial for Sirna-027 in AMD in 2005 and with its
strategic partner, Allergan, Inc., expects to move Sirna-027 into
Phase 2 clinical trials in 2006. Sirna has selected a clinical
compound for hepatitis C virus, Sirna-034, which the Company plans
to bring into Phase 1 clinical trials by the end of 2006. Sirna has
established an exclusive multi-year strategic alliance with
GlaxoSmithKline for the development of siRNA compounds for the
treatment of respiratory diseases. Sirna has a leading intellectual
property portfolio in RNAi covering over 250 mammalian gene and
viral targets and over 175 issued or pending patents covering other
major aspects of RNAi technology. More information on Sirna
Therapeutics is available on the Company's web site at
http://www.sirna.com/. Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. The development of Sirna-027 and
Sirna-034 as well as Sirna's other programs are still at a
relatively early stage and subject to significant risks and
unknowns. Moreover, Sirna's ability to develop products and operate
as a going concern requires significant cash to fund its operating
programs. In addition, patent applications may not result in issued
patents, and issued patents may not be enforceable or could be
invalidated. Other risks and uncertainties include, among others,
Sirna's early stage of development and short operating history,
Sirna's history and expectation of losses and need to raise
capital, Sirna's need to obtain clinical validation and regulatory
approval for Sirna-027, Sirna-034 and Sirna's other product
candidates, any of which could have negative results, Sirna's need
to engage collaborators, Sirna's need to obtain and protect
intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including the Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Rebecca Galler
Robison Senior Director, Corporate Strategy Sirna Therapeutics,
Inc. 303-449-6500 Francesca DeMartino The Ruth Group (646) 536-7024
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Rebecca Galler
Robison, Senior Director, Corporate Strategy of Sirna Therapeutics,
Inc., +1-303-449-6500; or Francesca DeMartino of The Ruth Group,
+1-646-536-7024, , for Sirna Therapeutics, Inc. Web site:
http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Oct 2023 to Oct 2024